COMUNICADO: Los médicos piden una mejor guía sobre el uso de las estatinas en pacientes con alto riesgo de desarrollar diabetes (y 2

 

COMUNICADO: Los médicos piden una mejor guía sobre el uso de las estatinas en pacientes con alto riesgo de desarrollar diabetes (y 2

Actualizado 14/11/2012 10:06:49 CET

[TAB] 1) Datos en archivo de Kowa. Informe sobre la consulta en el simposio satélite patrocinado por KOWA durante el World Congress on Prevention of Diabetes and

its Complications (WCPD) del 11 al 14 de noviembre de 2012 en Madrid, España.

2) Sponseller CA, Stender S, Zhu B, et al. Neutral effects of pitavastatin and

pravastatin on fasting plasma glucose over 12 weeks in elderly patients with primary

hyperlipidemia or mixed lipidemia. Abstract 2421526. Presented at the 7th World

Congress on Prevention of Diabetes and its Complications 2012. Madrid, España.

3) Hounslow N, Robillard P, Suzuki M, et al. Pitavastatin is without effect on

glycaemic parameters in metabolic syndrome. Abstract 7161542. Presented at the 7th

World Congress on Prevention of Diabetes and its Complications 2012. Madrid, España.

4) Armitage J. The safety of statins in clinical practice. Lancet.

2007;370:1781-90.

5) Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes:

a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716

):735-742.

6) Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and

increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol

2010;55:1209-1216.

7) Sabatine MS, Wiviott SD, Morrow DA, et al. High-dose atorvastatin associated

with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circ. 2004;110(Suppl 3):834.

8) Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose

tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb.

2008;15:269-275.

9) Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with

type 2 diabetes mellitus: subanalysis of the collaborative study on

hypercholesterolemia drug intervention and their benefits for atherosclerosis

prevention (CHIBA study). J Atheroscler Thromb. 2009;16:297-298.

10) Teramoto T, Urashima M, Shimano H, et al. A large-scale study on

cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese

patients with hypercholesterolemia LIVES 5-year extension study. Jpn Pharmacol Ther.

2011;39:789-803.

11) Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin:

efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11:817-828.

12) Saku K, Zhang B, Noda K, et al. Randomized head-to-head comparison of

pitavastatin, atorvastatin and rosuvastatin for safety and efficacy - The PATROL

study. Circ J. 2011;75(6):1493-505.

13) Kryzhanovski V, Morgan R, Sponseller C et al. Pitavastatin 4mg provides

significantly greater reduction in LDL-C compared to pravastatin 40mg with neutral

effects on glucose metabolism: prespecified safety analysis from the short-term phase

4 prevail UK trial in patients with primary hyperlipidemia or mixed dyslipidemia.

JACC. 2012;59:E1692

14) Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on

insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes

Res Clin Pract. 2010;87(1):98-107.

15) Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy

and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type

2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab.

2011;13(11):1047-55.

16) Kryzhanovski V, Eriksson M, Hounslow N and Sponseller C. Short-term and

long-term effects of pitavastatin and simvastatin on fasting plasma glucose in

patients with primary hyperlipidemia or mixed dyslipidemia and >2 risk factors for

coronary heart disease. J Am Coll Cardiol. 2012;59(13s1):E1659.

17) Yamazaki T, Kishimoto J, Ito C et al. Japan Prevention Trial of Diabetes by

Pitavastatin in Patients With Impaired Glucose Tolerance (the J-PREDICT study):

rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int.

2011;2:134-40.

18) Pitavastatin Summary of Product Characteristics. Disponible en

http://www.kowapharmaceuticals.eu/_client/pdfs/livazo_smpc.pdf Consultado en

septiembre de 2012

[FTAB]

CONTACTO: Para más información: Abigail Dewberry, Ruder Finn UK, 14 Nov. (0) - 7841-009249, +44(0)20-7438-3051, adewberry@ruderfinn.co.uk

Europa Press Comunicados Empresas
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies